Private Equity Addiction Treatment: Top Firms in 2026

Key Facts

• Private equity firms own 1,152 of 16,174 substance use disorder (SUD) treatment facilities in the United States, representing 7.1% of the total as of 2023.
• PE penetration is sharply higher in opioid treatment programs: 562 of 1,932 OTPs (29.1%) are PE-owned, and three parent companies control 54.6% of all PE-controlled OTPs nationally.
• Capital deployed into addiction treatment facilities reached $2.9 billion in 2016, up from just $11.4 million in 2011, reflecting a structural shift in institutional investment appetite for the sector.
• The addiction treatment industry generated $9.5 billion in revenue in 2016 and is projected to grow by an additional $10 billion, roughly doubling in size by the end of the decade.
• Virginia has the highest state-level SUD facility PE ownership rate at 22.1%; Montana, Nebraska, and South Dakota each report 100% PE ownership of opioid treatment programs.
• Behavioral health M&A activity peaked at 127 transactions in 2021, with approximately 60% of all behavioral health deals since 2018 involving private equity.
• EBITDA (earnings before interest, taxes, depreciation, and amortization) multiples for addiction treatment acquisitions range from 3x to 8x for small facilities to 14x to 16x for large scaling platforms.

Addiction Treatment Sector Overview

The market for private equity addiction treatment investment is built on a structural gap between supply and demand. In 2018, 164.8 million Americans used substances, but only 11% received care at a specialized facility. Fund managers identified both the clinical need and a revenue opportunity that institutional capital had largely ignored.

The Affordable Care Act mandated SUD coverage as an essential health benefit. The Mental Health Parity and Addiction Equity Act required commercial insurers to cover addiction treatment on par with other medical conditions. Together, these laws gave PE investors an expanding revenue base and a lasting regulatory tailwind.

The sector spans multiple sub-segments with distinct economic profiles. Premium private-pay residential rehabilitation centers charge $20,000 to $150,000 or more per stay, targeting commercially insured or self-pay patients. Opioid treatment programs (OTPs) dispensing methadone and buprenorphine serve a broader Medicaid population with predictable recurring visit volumes.

Outpatient SUD platforms, including intensive outpatient programs (IOP) and partial hospitalization programs (PHP), offer lower per-episode costs and broader payer acceptance. Sober living facilities, detox centers, and integrated mental health and SUD practices complete the acquisition universe.

The sector sits at the intersection of public health urgency and historically fragmented ownership. Roughly 80,000 opioid overdose deaths occur annually, sustaining regulatory pressure to expand treatment access and public reimbursement for SUD services. While venture capital has historically backed digital health companies adjacent to clinical treatment, PE investors have moved into direct facility ownership.

Publicly traded operators including Acadia Healthcare and American Addiction Centers defined the institutional playbook. American Addiction Centers' 2020 bankruptcy and the subsequent wave of PE consolidation illustrated both the sector's growth potential and its financial fragility. The South accounts for 39.15% of all PE-owned OTPs, the Midwest for another 25.09%, making these the dominant geographies for investment activity.

The Northeast holds only 12.99% of PE OTPs despite its population density.

Behavioral Health PE Firms: Comparison

The following table covers the most active private equity investors in addiction treatment and substance use disorder services. Strategy and sector focus differentiate these firms more meaningfully than assets under management (AUM). Individual fund sizes carry limited public disclosure across the sector.

Webster Equity Partners and Shore Capital Partners dominate the buyout tier by platform scale and deal volume. Avesi Partners and LLR Partners represent the growth equity approach, targeting earlier-stage providers where clinical differentiation, rather than geographic scale, drives the investment thesis.

Top Picks by Investment Strategy

Largest Active Platform: Webster Equity Partners assembled BayMark Health Services into a 400-plus-facility, 37-state addiction treatment network through systematic add-on acquisitions, including 29 announced deals since 2019 alone.

Growth Equity Leader: Avesi Partners, with $880 million in equity capital under management, applies a lower-middle market growth equity framework to behavioral health providers spanning addiction treatment, adolescent mental health, and special education.

Top OTP Consolidator: Revelstoke Capital Partners executed the methadone clinic roll-up strategy ahead of the 2020 Medicare OTP reform, which created new reimbursement pathways that substantially improved the financial attractiveness of opioid treatment programs for institutional investors.

Strongest Microcap Track Record: Shore Capital Partners closed its sixth healthcare buyout fund at $850 million, concentrating on sub-$20 million EBITDA businesses that are too small for large buyout firms but benefit significantly from institutional operating support.

Most Active Deal Maker: BayMark Health Services, under Webster Equity's ownership, has completed more acquisitions than any other PE-backed platform in this sector since 2019, logging 29 announced transactions.

Residential Buyout Specialist: Kohlberg & Co. paid approximately $180 million for The Meadows, a nationally recognized residential treatment center in Wickenburg, Arizona, demonstrating premium willingness to pay for established clinical brands with defensible commercial payer relationships.

Insurance Expansion Play: Comvest Partners, through its Your Behavioral Health platform, acquired Insight Treatment Programs in 2024 to execute the credentialing-and-scale thesis in California's high-reimbursement commercial insurance market.

Top Behavioral Health Private Equity Firms in Detail

Webster Equity Partners

Webster Equity Partners assembled the most expansive platform in addiction treatment through BayMark Health Services, a 400-plus-facility operator spanning 37 states. The firm's thesis is buy-and-build consolidation: it acquires regional operators, standardizes payer credentialing and billing, then renegotiates insurance contracts from a position of geographic scale. The 2024 launch of PAX Health, combining BMA, WCPN, and Reservoir Health, shows Webster's continued appetite for new platform formation alongside the primary BayMark roll-up.

BayMark's 29 announced acquisitions since 2019 make Webster the firm most regional operators encounter as a prospective buyer in active U.S. addiction treatment markets.

Shore Capital Partners

Shore Capital Partners is the premier microcap healthcare buyout sponsor in addiction treatment, closing its sixth healthcare-dedicated fund at $850 million. Its behavioral health portfolio includes BrightView (addiction treatment and outpatient mental health), Transformations Care Network, and Column Health (serious mental illness). Shore focuses on providers with EBITDA under $20 million, a size range where larger buyout firms rarely compete.

The operator model drives value creation. Shore provides clinical operations infrastructure, revenue cycle management, and payer contracting resources that founder-owned treatment centers cannot build independently. Treatment center operators managing 3 to 7 locations seeking a structured growth partner before a larger exit will find Shore Capital among the most sector-focused sponsors active in this market.

Avesi Partners

Avesi Partners executes lower-middle market growth equity in behavioral health with $880 million in equity capital under management. Its platforms serve adolescents through adults across SUD treatment, mental health, and special education. The addiction treatment arm, First Steps Recovery, acquired Georgia Recovery Campus in December 2025, demonstrating continued deal activity despite the broader post-2021 slowdown in behavioral health M&A.

Avesi's portfolio companies share an evidence-based care mandate. Muir Wood (adolescent mental health) and Point Quest (adolescent behavioral health) reflect the clinical orientation that distinguishes Avesi from volume-oriented consolidators. Founders in the lower-middle market seeking a growth equity partner with genuine clinical standards will find Avesi among the most aligned investors in the sector.

Deerfield Management

Deerfield Management's $231.5 million commitment to Recovery Centers of America illustrates the East Coast residential platform thesis. Recovery Centers of America operates seven facilities focused on commercially insured patients. Deerfield backs operators with evidence-based clinical protocols and the management depth to scale geographically without diluting care standards.

The East Coast facility concentration creates referral network density that reduces patient acquisition costs per admission. For general partners presenting behavioral health investment theses to LP institutions, Deerfield's structured approach to clinical platform building is more analytically rigorous than the typical operational roll-up.

Lee Equity Partners

Lee Equity's decade-long behavioral health focus separates it from firms that entered SUD treatment opportunistically during the 2016 to 2021 deal surge. Its primary addiction treatment holding, Bradford Health, operates 40 SUD treatment and recovery centers across the Southeastern United States. The Southeast ranks among the highest regions nationally for PE penetration in opioid treatment programs.

The firm prioritizes operators with stable clinical staff tenure and established community referral relationships. Both factors directly correlate with patient census stability and average length of stay. Bradford Health's 40-center network generates meaningful payer negotiation leverage without requiring the national scale of a Webster Equity-style roll-up.

Comvest Partners

Comvest built Your Behavioral Health into a Southern California SUD treatment platform, then added Insight Treatment Programs in 2024 to execute the insurance credentialing expansion thesis. Research on SUD facility ownership shows that PE acquisition increases Medicare acceptance probability by 25 percentage points and Medicaid acceptance by 15.4 percentage points relative to independently owned comparators. This credentialing effect provides the revenue expansion model that justifies acquisition premiums on facilities with limited existing payer networks.

Comvest's California concentration reflects the state's above-average commercial insurance reimbursement rates, which elevate the per-EBITDA value of credentialed platforms.

Audax Private Equity

Audax Private Equity builds behavioral health through middle-market platform consolidation, with Meridian Behavioral Health as its primary multi-state addiction treatment and mental health investment. The Boston-based firm differentiates from pure consolidators by emphasizing shared operational services. Its backed companies access centralized revenue cycle management, compliance infrastructure, and HR functions that reduce overhead relative to independently operated regional providers.

Audax's behavioral health thesis prioritizes geographic density within defined markets. This approach creates referral network concentration that supports patient census and payer contracting outcomes without the regulatory exposure of a 37-state network.

Investment Trends Shaping Addiction Treatment PE

OTP Consolidation and Public Reimbursement Expansion

The 2020 Medicare OTP reform created a new reimbursement stream for methadone clinic services, converting OTPs into a Medicare-billable service category for the first time. PE responded by accelerating acquisitions in this sub-segment. Today, 29.1% of all 1,932 U.S. opioid treatment programs are PE-owned.

The top three PE parent companies control 54.6% of all PE-owned OTPs. This concentration has drawn active FTC scrutiny of roll-up strategies in the sub-sector.

Insurance Credentialing as the Core Value Creation Lever

PE acquirers systematically expand insurance acceptance at acquired facilities rather than redesigning clinical services. Before acquisition, approximately 17% of eventually-acquired establishments accepted no insurance at all. After acquisition, Medicare acceptance rises by 25 percentage points and Medicaid acceptance by 15.4 percentage points, with effects persisting for at least five years.

This credentialing playbook is the central financial mechanism fund managers deploy in addiction treatment.

Shift from Private-Pay Residential to Outpatient MAT

Premium private-pay residential rehab charges $20,000 to $150,000 per stay but reaches a narrow commercially insured population. Capital is moving toward outpatient medication-assisted treatment (MAT) platforms integrating buprenorphine and methadone prescribing that accept Medicaid at scale. CleanSlate, backed by HealthQuest Capital, built a network of 50-plus outpatient MAT centers in eight states, demonstrating this model's scalability at meaningful patient volume.

Telehealth and Digital Therapeutics Integration

While venture capital has funded digital therapeutics adjacent to clinical SUD care, PE-backed platforms are embedding telehealth buprenorphine prescribing and app-based recovery support tools to extend geographic reach without proportional facility investment. LLR Partners has positioned explicitly as a behavioral health technology investor, backing SUN Behavioral Health. The firm pursues technology-enabled treatment services as a distinct investment category within its behavioral health mandate.

Regulatory and Quality Scrutiny

SAMHSA accreditation requirements, state licensing variation, and active FTC investigation of healthcare roll-up strategies create material compliance risk for PE consolidators. Academic researchers at OHSU, Yale, and other institutions have documented PE ownership patterns across 16,000-plus SUD facilities and raised questions about care quality at holdings restricting access to evidence-based MAT. California's proposed PE disclosure requirements for healthcare transactions signal a legislative trend toward greater ownership transparency that could affect deal timelines and transaction costs.

How to Evaluate Behavioral Health PE Investors

Payer mix is the primary financial screen in addiction treatment due diligence. Facilities with 60% or higher commercial insurance revenue command higher EBITDA multiples. The credentialing expansion thesis holds that expanding Medicaid acceptance increases total patient volume even at lower per-patient reimbursement rates.

The optimal payer mix depends on acquisition strategy. Premium residential platforms optimize for commercial concentration, while outpatient MAT networks optimize for Medicaid volume and census stability.

Regulatory compliance history is a non-negotiable diligence item. Anti-kickback violations in patient referral arrangements, fraudulent urine drug testing billing, and state licensing deficiencies have resulted in criminal prosecutions and facility closures across the sector. Any target with open federal investigations, prior licensing suspensions, or documented referral fee arrangements requires independent legal review before closing.

Clinical quality metrics determine long-term asset performance. Facilities offering evidence-based MAT with buprenorphine or methadone demonstrate lower patient relapse rates, which directly supports census stability and average length of stay. SAMHSA accreditation, Joint Commission certification, and CARF accreditation are the recognized quality signals.

Only New York and Massachusetts legally require addiction treatment centers to offer medications for opioid use disorder. Clinical protocol quality varies widely in other states. LPs evaluating behavioral health PE fund commitments should assess each general partner's track record across prior funds, including internal rate of return (IRR) and fund-level multiple on invested capital.

PE consolidators targeting a 10x to 15x EBITDA exit require a management structure capable of integrating add-on acquisitions without clinical disruption. Founder-operated platforms without a second tier of operational leadership typically need 12 to 18 months of institutional investment before they are integration-ready.

Which Firm Fits Your Needs?

Treatment center operators managing regional networks of 3 to 10 facilities will find Shore Capital Partners and Avesi Partners the most operationally aligned sponsors. Both target lower-middle market healthcare, bring dedicated behavioral health operating teams, and structure transactions to retain founder equity participation in add-on acquisition upside. Operators of a single premium residential facility with a strong commercial payer mix are more likely to attract Kohlberg & Co. or Lee Equity Partners.

Both Kohlberg and Lee Equity have paid 10x or higher EBITDA multiples for clinical brands with defensible payer contracts and clean compliance histories. LPs building diversified alternatives exposure to behavioral health should evaluate Shore Capital and Avesi Partners as sector-specialist vehicles, each with disclosed fund sizes and concentrated investment mandates.

Webster Equity Partners, through BayMark's 37-state platform, represents the large-cap end of the spectrum. Geographic diversification moderates single-site regulatory risk but reduces the return potential available to earlier-stage consolidators with dry powder still being deployed. Advisors and investment bankers mapping deal flow should note that BayMark Health Services, under Webster Equity, remains the most aggressive acquirer by volume at roughly six deals annually since 2019.

Comvest Partners leads the insurance credentialing expansion strategy in California. Audax Private Equity and Lee Equity represent the disciplined mid-market approach for Southeastern and multi-state platforms. Founders and investors focused specifically on OTP assets should engage Revelstoke Capital Partners first, given its specialist positioning in the methadone clinic sub-segment.

Methodology

This analysis of private equity addiction treatment activity draws on peer-reviewed research in health policy and medical journals examining PE ownership and outcomes in substance use disorder treatment through 2025. Market statistics reference SAMHSA's National Survey of Substance Abuse Treatment Services and the National Substance Use and Mental Health Services Survey, along with M&A transaction databases covering healthcare deals from 2014 through 2025. Individual firm profiles rely on publicly available portfolio disclosures, press releases, and announced transaction data.

EBITDA multiple ranges reflect published deal advisory benchmarks from behavioral health M&A specialists active in the sector. All statistics cited in this article are sourced from studies and data published between 2021 and 2025.